Abstract
Clinical Practice Points Cunninghamella, a relatively infrequent cause of mucormycosis, is associated with aggressive and often fatal disseminated invasive fungal infection in hematopoietic stem cell transplant (HSCT) recipients, in particular those receiving high-dose immune suppression. Polyene-based antifungal agents, such as amphotericin B and its lipid derivatives, are first-line therapy for invasive mucormycosis. Despite currently available treatment approaches, the attributable mortality of mucormycosis remains very high. Our single-center experience suggests that infection with Cunninghamella species portends worse outcomes. The impact of prophylactic approaches (eg, with extended-spectrum azoles such as posaconazole) in preventing this infection in high-risk patients awaits further investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
